1. Autophagy in cancer stem/progenitor cells

   • Yi-Hui Lin
   • Yu-Chun Huang
   • Pei-Ming Chu

   Review Article 26 November 2014 Pages: 879 - 886

2. Unexpected hepatotoxicity in a phase I study of TAS266, a novel tetravalent agonistic Nanobody^® targeting the DR5 receptor

   • Kyriakos P. Papadopoulos
   • Randi Isaacs
   • Amit Mahipal

   Original Article 27 February 2015 Pages: 887 - 895

   

3. Preclinical examination of clofarabine in pediatric ependymoma: intratumoral concentrations insufficient to warrant further study

   • Yogesh T. Patel
   • Megan O. Jacus
   • Clinton F. Stewart

   Original Article 28 February 2015 Pages: 897 - 906

   

4. The effect of food on the pharmacokinetics of oral ibrutinib in healthy participants and patients with chronic lymphocytic leukemia

   • Jan de Jong
   • Juthamas Sukbuntherng
   • Erik Mannaert

   Original Article Open access 28 February 2015 Pages: 907 - 916

   

5. Activated STAT3 correlates with prognosis of non-small cell lung cancer and indicates new anticancer strategies

   • Yang Yu
   • Qian Zhao
   • Xiang-Yan Liu

   Original Article 04 March 2015 Pages: 917 - 922

   

6. Plasma and cerebrospinal fluid pharmacokinetics of the Akt inhibitor, perifosine, in a non-human primate model

   • Diane E. Cole
   • Cynthia M. Lester-McCully
   • Katherine E. Warren

   Original Article 05 March 2015 Pages: 923 - 928

   

7. First-in-human, phase I/IIa dose-escalation and safety study of balugrastim in breast cancer patients receiving myelosuppressive chemotherapy

   • Noa Avisar
   • Liat Adar
   • Laurie Pukac

   Original Article 05 March 2015 Pages: 929 - 939

   

8. Sequential treatment with epirubicin, oxaliplatin and 5FU (EOF) followed by docetaxel, oxaliplatin and 5FU (DOF) in patients with advanced gastric or gastroesophageal cancer: a single-institution experience

   • Roberto Petrioli
   • Edoardo Francini
   • Giandomenico Roviello

   Original Article 06 March 2015 Pages: 941 - 947

   

9. Ginkgolide B protects against cisplatin-induced ototoxicity: enhancement of Akt–Nrf2–HO-1 signaling and reduction of NADPH oxidase

   • Weijun Ma
   • Juan Hu
   • Min Xu

   Original Article 07 March 2015 Pages: 949 - 959

   

10. Effects of cyclosporine A on the hepatobiliary disposition and hepatic uptake of etoposide in an isolated perfused rat liver model

    • Mina Khezrian
    • Behjat Sheikholeslami
    • Mohammadreza Rouini

    Original Article 11 March 2015 Pages: 961 - 968

    

11. Levels of sirolimus in saliva and blood following oral topical sustained-release varnish delivery system application

    • Zakhar Nudelman
    • Mordechai Findler
    • Rakefet Czerninski

    Original Article 11 March 2015 Pages: 969 - 974

    

12. Pharmacokinetically based dosing of weekly paclitaxel to reduce drug-related neurotoxicity based on a single sample strategy

    • Stefanie Kraff
    • Annemieke J. M. Nieuweboer
    • Markus Joerger

    Original Article 12 March 2015 Pages: 975 - 983

    

13. Organic cation transporter OCT6 mediates cisplatin uptake and resistance to cisplatin in lung cancer

    • Eiji Kunii
    • Tetsuya Oguri
    • Akio Niimi

    Original Article 14 March 2015 Pages: 985 - 991

    

14. Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer

    • Niall Tebbutt
    • Dusan Kotasek
    • David Goldstein

    Original Article 15 March 2015 Pages: 993 - 1004

    

15. Positron emission tomography imaging of human colon cancer xenografts in mice with [¹⁸F]fluorothymidine after TAS-102 treatment

    • Haeng Jung Lee
    • Seung Jun Oh
    • Tae Won Kim

    Original Article 17 March 2015 Pages: 1005 - 1013

    

16. Plasma pharmacokinetics of the indenoisoquinoline topoisomerase I inhibitor, NSC 743400, in rats and dogs

    • Miguel Muzzio
    • Shu-Chieh Hu
    • Jan H. Beumer

    Original Article 17 March 2015 Pages: 1015 - 1023

    

17. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor

    • Inkeun Park
    • Jae-Lyun Lee
    • Hanjong Ahn

    Original Article 17 March 2015 Pages: 1025 - 1035

    

18. Dose selection of siltuximab for multicentric Castleman’s disease

    • Christina L. Mayer
    • Lanyi Xie
    • Thomas A. Puchalski

    Original Article 18 March 2015 Pages: 1037 - 1045

    

19. Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies

    • Margaret von Mehren
    • Michael Bookman
    • Roger B. Cohen

    Original Article 20 March 2015 Pages: 1047 - 1055

    

20. Protective effects of C-type natriuretic peptide on cisplatin-induced nephrotoxicity in Mice

    • Toru Kimura
    • Takashi Nojiri
    • Kenji Kangawa

    Original Article 27 March 2015 Pages: 1057 - 1063

    

21. A phase I trial of intravenous catumaxomab: a bispecific monoclonal antibody targeting EpCAM and the T cell coreceptor CD3

    • Morten Mau-Sørensen
    • Christian Dittrich
    • Josep Tabernero

    Original Article 27 March 2015 Pages: 1065 - 1073

    

22. A phase I study of intraperitoneal nanoparticulate paclitaxel (Nanotax^®) in patients with peritoneal malignancies

    • Stephen K. Williamson
    • Gary A. Johnson
    • Charles J. Decedue

    Clinical Trial Report 23 April 2015 Pages: 1075 - 1087

    

23. Mercaptopurine metabolite levels are predictors of bone marrow toxicity following high-dose methotrexate therapy of childhood acute lymphoblastic leukaemia

    • Sophia Ingeborg Vang
    • Kjeld Schmiegelow
    • Jacob Nersting

    Short Communication 19 March 2015 Pages: 1089 - 1093

    

24. Validation of a fast and low-cost alkaline lysis method for gDNA extraction in a pharmacogenetic context

    • Ruth Ramos-Díaz
    • Fernando Gutiérrez-Nicolás
    • José A Pérez-Pérez

    Short Communication 25 March 2015 Pages: 1095 - 1098